Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilastPDE4 inhibitors: current statusPharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?COPD exacerbations. 4: PreventionCilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.Airways disease: phenotyping heterogeneity using measures of airway inflammation.Influencing the decline of lung function in COPD: use of pharmacotherapy.Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages.Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.ABCD of the phosphodiesterase family: interaction and differential activity in COPDRoflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activitiesAirway inflammation in children with difficult asthma: relationships with airflow limitation and persistent symptoms.Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2003.Measuring bronchodilation in COPD clinical trials.An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease.Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.Differential distribution of inflammatory cells in large and small airways in smokers.Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolPDE4 inhibition suppresses IL-17-associated immunity in dry eye diseaseAnti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma.Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDTaming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control.Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?Pulmonary biomarkers in chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Update in chronic obstructive pulmonary disease 2005.Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors.Alveolar macrophages as orchestrators of COPD.Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokinesPhosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.Evaluation of PDE4 inhibition for COPD.Pharmacological treatment of chronic obstructive pulmonary disease.Biological targets for therapeutic interventions in COPD: clinical potentialEosinophilic airway inflammation in COPDFuture therapeutic treatment of COPD: struggle between oxidants and cytokines
P2860
Q24202545-14D99AE3-E409-482A-BDFA-A9B2E96097E6Q24234493-AF808C70-FA8F-4BD7-A8EE-736199BAF426Q24646836-E1F6BE53-6AF8-416F-986D-231C379B31FFQ24651926-EADB360B-A325-42E8-84B2-6DB6CAA28B07Q26777927-4C9FD4AE-FC53-412A-B7B4-F44E7BC7A828Q30480789-B6A65A87-A4BB-4BB7-959E-C578B139FAB9Q33258089-18513940-5FDE-4F41-9635-8C5296CB3157Q33864952-218E171F-C616-4233-BB82-18ADF1B55077Q33966001-8088987A-590B-4FFE-AC45-053A3E7D5CEEQ34475700-FF842524-F5C0-4B47-BA68-9513BAAA150FQ34578865-CF214D47-7759-4B2C-BB78-55B19C3BF7EAQ34961511-66941EB4-0AC6-4373-80FF-B9E26E1F1CF1Q34997388-FEC19482-A2AD-4C0A-9518-6AAD901F89FEQ35048762-8B8E2386-CB01-4491-B374-EEFA44C09306Q35536236-1BA562B5-0EAE-43E3-A8A6-25CAF9938C8AQ35626624-501FFEF5-1A00-471B-B9C8-4B5F112BC1F7Q35826850-33D91449-582B-4DAF-A44B-FE4312FC1E46Q35827644-06C5B96D-D7D2-469B-BF9B-31A583E2E493Q35842492-7659B0F0-3CF3-4E2B-B9C2-837205F9B8ADQ35876360-0D531954-976D-4FA0-896F-00AF56CE6450Q36014272-0451D8B8-52D7-4030-B488-DD5530115253Q36086153-DB0E37E1-F870-434C-8AF5-CB07300FD247Q36122993-21265A72-EAAC-4561-87B7-F137918D90CCQ36145839-156FBF70-A00D-47DB-97C9-239977C8AFFEQ36165890-B8260D3C-5918-458C-A9C8-05C0D758786AQ36169173-7FAA20A7-4EC9-415C-8112-58AE71E715ECQ36183282-C4B4C130-D2B2-49C1-A0CC-4A9F826CC691Q36376519-DD0EFD57-BDA8-4C91-8B75-6728C14ABF6FQ36429908-EEE3C2C9-8E85-4B71-82BD-9DA2A7A5BC04Q36443665-1B9DCF94-8F54-4317-8B54-16D5D8423F2DQ36470462-81C13C28-3DAA-42FC-9E03-65AFBDEEC56DQ36554689-15581448-6432-4398-8681-CFBBB96CEAECQ36602291-15F569AF-93B8-4A60-9D10-3DB779D45129Q36648886-DFE58A18-3E71-4678-A6D6-C2B34B0BC5FBQ36792648-C74CEA75-5052-4279-BF52-BF0ED374BB77Q37017332-AB91EB26-0702-4E86-9E4F-0342A79D6BD2Q37017344-BCE8C741-B13F-4A01-BA5E-83C00A0AC93AQ37018843-233F1F29-7529-43AD-8E8B-3470FFDDF75FQ37018920-A506942E-73FB-4ED5-A35C-B982BBDB2265Q37071004-E542A916-19DF-4311-BBA3-A4551FA35D0E
P2860
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Antiinflammatory effects of th ...... obstructive pulmonary disease.
@en
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast
@nl
type
label
Antiinflammatory effects of th ...... obstructive pulmonary disease.
@en
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast
@nl
prefLabel
Antiinflammatory effects of th ...... obstructive pulmonary disease.
@en
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast
@nl
P2093
P2860
P1476
Antiinflammatory effects of th ...... obstructive pulmonary disease.
@en
P2093
Antonio M Vignola
Christopher Compton
Christopher E Brightling
Claus Kroegel
Dean Matin
Debbie Parker
Diana C Grootendorst
Elizabeth Gamble
Ferran Morell
Jeffrey Edelson
P2860
P304
P356
10.1164/RCCM.200212-1490OC
P407
P577
2003-06-19T00:00:00Z